Torrey Pines Institute for Molecular Studies and The Tri-Institutional Therapeutics Discovery Institute Announce Strategic Agreement

July 25, 2017

Partnership Intends to Accelerate Drug Discovery by Utilizing Torrey Pines' Compound Libraries and Screening Technologies

Port St. Lucie, Fla., Torrey Pines Institute for Molecular Studies, Inc. (TPIMS) today announced a strategic agreement with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI). TPIMS has built a collection of compounds and corresponding technologies enabling the rapid screening of up to trillions of unique compounds by testing only hundreds of samples to identify individual hit compounds for development. The mission of the Tri-I TDI is to advance groundbreaking biological discoveries to preclinical studies by providing industrial-scale technical support for academic projects, making it possible to rapidly assess the utility of specific therapeutic targets in disease-relevant contexts.

"We are pleased to partner with Tri-I TDI and provide our compound collection," said Richard Houghten, Ph.D., Founder and CEO, TPIMS. "Our technologies can enable high-throughput screening in a variety of biological assay formats, including phenotypic assays. This collaboration aims to accelerate drug discovery, ultimately providing new therapies to treat human diseases." Through this partnership, TPIMS will provide Tri-I TDI with the TPIMS compound collection for screening to identify hit compounds within Tri-I TDI research programs. This provides Tri-I TDI with capabilities to perform high-throughput screening across a variety of assay platforms with TPIMS' unique compound collection.

"We believe that access to the TPIMS compound collection will enhance our ability to deliver on our mission. Leads from these collections should enable the progression of groundbreaking academic discoveries to preclinical studies in order to demonstrate their relevance in blocking disease initiation and progression," stated Peter T. Meinke, Ph.D., VP, Preclinical Development, Tri-I TDI.

About the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI)

The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) connects researchers from Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine with collaborators from across the globe to remove the barriers that impede drug discovery in academic settings. Together with its partners, Takeda Pharmaceuticals and Bridge Medicines, the Tri-I TDI enables the discovery of next-generation drugs by empowering faculty with the tools, technology, and expertise to meet this extraordinary challenge. This partnership leverages combined resources to help academic researchers rapidly advance their groundbreaking discoveries along the path from bench to bedside.

About Torrey Pines Institute for Molecular Studies (TPIMS)

Torrey Pines Institute for Molecular Studies (TPIMS) is a non-profit institute dedicated to conducting basic research to advance the understanding of human disease and the improvement of human health. TPIMS' scientists conduct research in fields associated with a wide variety of major medical conditions, including addiction, Alzheimer's, arthritis, cancer, diabetes, heart disease, infectious disease, inflammatory disorders, multiple sclerosis, obesity, pain management, regenerative medicine and new methods for drug discovery.


Greg Welmaker, Ph.D., MBA
President, COO, & Director of Drug Discovery
This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: (772) 345-4582

More Articles...

  1. Senate President Joe Negron Appoints Dr. Richard Houghten to the Biomedical Research Advisory Council for the State of Florida's Department of Health
  2. Torrey Pines Institute’s Board Appoints Dr. Gregory S. Welmaker as President
  3. Torrey Pines Institute Hosts Three Japanese Students from Hoshi University
  5. Torrey Pines Institute’s Dr. Lawrence Toll and Dr. Akihiko Ozawa Awarded $2.1 Million Grant
  6. TPIMS to Provide Uniquely Focused Technology for NCI (NExT) Program
  8. Torrey Pines Institute’s Dr. Predrag Cudic Awarded Grant over $1.3 Million
  9. Torrey Pines Institute Welcomes New Collaborators to the Florida Drug Discovery Acceleration Program
  10. Akron Biotech Awarded SBIR Grant for Development of Novel Method to Isolate Adipose Derived Stem Cells
  11. Torrey Pines Institute Awarded $3.1 Million for Inflammation and Autoimmune Disease in Bi-Coastal Collaboration
  12. Florida Drug Discovery
  13. IRSC and Torrey Pines Announce New Work-Study Internship Program
  14. Torrey Pines Institute for Molecular Studies Initiates Research Collaboration with Takeda
  15. Libby Handel, Ph.D. Joins Torrey Pines Institute as Director of Business Development
  16. Dr. Vipin Kumar awarded $2 million grant to fight alcohol liver disease
  17. Dr. Barbara Mueller awarded $2 million grant to fight breast cancer
  18. STEM Internships at Torrey Pines Institute Offer Hands-on Educational Experience to Students
  19. Local High School Science Teacher Earns Practical Lab Experience as Teacher Intern
  20. Researchers discover mechanism that helps control blood cell production in bone marrow